Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Priyanka Yalamanchili¹, Lydia Lee², Greta Bushnell³, Melissa Mannion⁴, Chintan Dave⁵ and Daniel B. Horton⁶, ¹Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Morris Plains, NJ, ²Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, NJ, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ, ⁶Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…
Abstract Number: 0832 • ACR Convergence 2024
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Sarah McCuaig¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 1283 • ACR Convergence 2024
Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus
Meredith Rae¹, Emily Beil², Juan Carlos Torres², Kristen Fisher² and Eyal Muscal³, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Transverse myelitis (TM) has an incidence of 1-2% in pediatric SLE and is often a feature of early disease. Most patients ( >60%) have…
Abstract Number: 1769 • ACR Convergence 2024
Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Ujana Zajmi¹, Megan Darrell¹, Amy Kaneshiro¹, Adeline Chin¹, Adriana Jesus², Stephen Brooks¹, Raphaela Goldbach-Mansky², Lisa Rider³ and Hanna Kim⁴, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NIAD, Bethesda, MD, ³NIEHS, NIH, Garrett Park, MD, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Myositis-specific autoantibody (MSA) subgroups define phenotypes associated with specific clinical traits and outcomes within JDM, a clinically heterogeneous autoimmune disease. The pathogenesis of JDM…
Abstract Number: 1932 • ACR Convergence 2024
Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology
Chrisana Pokorny¹ and Bethany Marston², ¹University of Rochester, Webster, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Pediatric to adult transition is often challenging among young adults with rheumatic diseases. Structured transition programs can improve adherence to care, quality of life,…
Abstract Number: 2189 • ACR Convergence 2024
Migratory Arthritis in Children: What Besides Rheumatic Fever?
bar goldberg¹, Gil Amarilyo², oded Scheuerman¹, tarek Zuabi³, alina Guz¹, Maayan Ravia¹ and yoel Levinsky¹, ¹schneider medical center, petah tikva, Israel, ²Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Kibbutz Maggal, HaMerkaz, Israel, ³schneider medical center, petah tikva
Background/Purpose: Migratory Arthritis, a not uncommon presentation in pediatrics, is classically associated with rheumatic fever (RF), although can be the first presentation of other medical…
Abstract Number: 2207 • ACR Convergence 2024
Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Brian Feldman⁹, Raju Khubchandani¹⁰, Tadey Avcin¹¹, Sindhu R. Johnson¹², Mikhail Kostik¹³, Edoardo Marrani¹⁴, Flavio Sztajnbok¹⁵, Maria Katsicas¹⁶, Dana Nemcova¹⁷, Maria Jose Santos¹⁸, Simone Appenzeller¹⁹, Cristina Battagliotti²⁰, Lillemor Berntson²¹, Jürgen Brunner²², Liora Harel²³, Gerd Horneff²⁴, Tilmann Kallinich²⁵, Kirsten Minden², Farzana Nuruzzaman²⁶, Anjali Patwardhan²⁷, Dieneke Schonenberg-Meinema²⁸ and Nicola Helmus²⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Cerrahpasa Medical School, Istanbul, Turkey, ⁵Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁶UNIFESP, São Paulo, SP, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ¹⁰SRCC Childrens Hospital, Mumbai, India, ¹¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹²University of Toronto, Toronto, Canada, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴University of Florence, Firenze, Florence, Italy, ¹⁵UFRJ/UERJ, SAO PAULO, Brazil, ¹⁶Hospital Garrahan, Buenos Aires, Argentina, ¹⁷MD, Prague, Czech Republic, ¹⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹⁹Unicamp, Campinas, SP, Brazil, ²⁰Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²¹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ²³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ²⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁵Charite, Berlin, Germany, ²⁶Stony Brook Children's Hospital, Stony Brook, NY, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jessica Neely¹, Peter Shrader², Stacey Tarvin³, Kaveh Ardalan⁴, Susan Shenoi⁵, Adam Huber⁶, Susan Kim⁷ and Hanna Kim⁸, and for the CARRA Registry Investigators, ¹UCSF, San Francisco, CA, ²Duke Clinical Research Institute, Durham, NC, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Duke University School of Medicine, Durham, NC, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷University of California, San Francisco, CA, ⁸National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…
Abstract Number: 0370 • ACR Convergence 2024
Adolescents’ and Providers’ Perceptions of the Transition from Pediatric to Adult Rheumatology
Julia Witowska, Brett Curtis, Melanie Donahue, Sara Platte, Rebecca Northway and Jacqueline Madison, University of Michigan, Ann Arbor, MI
Background/Purpose: The transition from pediatric to adult rheumatology is a vulnerable period for adolescents and is associated with greater disease burden. Adolescents require an organized…
Abstract Number: 0398 • ACR Convergence 2024
Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Mary Eckert¹, Eveline Wu², Melissa Oliver³, Joshua Scheck⁴, Sivia Lapidus⁵, Ummusen Kaya Akca⁶, Shima Yasin⁷, Aleksander Lenert⁸, Sara Stern⁹, Antonella insalaco¹⁰, Manuela Pardeo¹⁰, Gabriele Simonini¹¹, Edoardo Marrani¹², Xing Wang¹³, Bin Huang¹⁴, Leonard Kovalick¹⁵, Natalie Rosenwasser¹⁶, Erin Balay-Dustrude¹⁷, Gabriel Casselman¹⁶, Liau Adriel¹⁸, Ava Klein¹⁸, Yurong Shao⁴, Claire Yang⁴, Molly Briggs⁴, Emily Deng⁴, Iris Hamilton⁴, Ethan Mueller¹⁶, Elise Machrone⁴, Paige Trunnel⁴, Doaa Mosa¹⁹, Lori Tucker²⁰, Hermann Girschick²¹, Ronald Laxer²², Georgina Tiller²³, Jonathan Akikusa²⁴, Christian Hedrich²⁵, Karen Onel²⁶, Fatma Dedeoglu²⁷, Marinka Twilt²⁸, Seza Ozen²⁹, Polly Ferguson³⁰, Laura Schanberg³¹, Bryce Reeve³² and Yongdong (Dan) Zhao³³, ¹Seattle Children's, Mercer Island, WA, ²University of North Carolina School of Medicine, Chapel Hill, NC, ³Indiana University, Indianapolis, IN, ⁴Seattle Children's Hospital, Seattle, ⁵Hackensack University Medical Center, Montclair, NJ, ⁶Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁷University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, ⁸University of Iowa, Iowa City, IA, ⁹University of Utah, Salt Lake City, UT, ¹⁰IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹¹Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹²University of Florence, Firenze, Florence, Italy, ¹³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ¹⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ¹⁵UNC Health Care, Durham, NC, ¹⁶Seattle Children's Hospital, Seattle, WA, ¹⁷University of Washington, Seattle, WA, ¹⁸Seattle Children’s Research Institute, University of Washington, Seattle, ¹⁹Mansoura University Hospital, Mansoura City, Egypt, ²⁰BC Children's Hospital, Vancouver, BC, Canada, ²¹Vivantes Clinic Friedrichshain, Wuerzburg, Germany, ²²SickKids, Toronto, ON, Canada, ²³University of British Columbia - Vancouver, Vancouver, BC, Canada, ²⁴Royal Children's Hospital, Parkville, Victoria, Australia, ²⁵University of Liverpool, Liverpool, United Kingdom, ²⁶HSS, New York, NY, ²⁷Boston Children's Hospital, Boston, MA, ²⁸Alberta Children's Hospital, Calgary, AB, Canada, ²⁹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³⁰University of Iowa Carver College of Medicine, Iowa City, IA, ³¹Duke University Medical Center, DURHAM, NC, ³²Duke University School of Medicine, Durham, ³³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
Abstract Number: 0921 • ACR Convergence 2024
Deep Immunologic Profiling of Trisomy 8-associated Autoinflammatory Disease (TRIAD)
Kalpana Manthiram¹, Lihong Shi¹, Yue Zhang², Bayu Sisay³, Shouguo Gao⁴, Zhijie Wu⁴, Qin Xu¹, Mary Bowes², Laura Failla², Neelam Redekar², Abdel Elkahloun³, Pamela Schwartzberg¹ and Daniel Kastner³, ¹National Institute of Allergy and Infectious Disease, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, Bethesda, MD
Background/Purpose: Trisomy 8 mosaicism is associated with an inflammatory disease characterized by recurrent fever and oral, genital, and gastrointestinal ulcers, resembling Behçet’s disease. Little is…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
Abstract Number: 1284 • ACR Convergence 2024
Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center
keerthivardhan yerram¹, phanikumar devarasetti¹ and Liza Rajasekhar², ¹Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disorder that predominantly affects the skin and muscles in children under the age of sixteen. Literature on…
Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Mireia Lopez Corbeto¹, yolanda Guillen², Irene Bonafonte³, Nuria Palau⁴, Raül Tortosa⁴, Estefanía Moreno Ruzafa¹, Antonio Julia⁵ and Sara Marsal⁶, ¹Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Berufserfahrung: Helmholtz Munich, Barcelona, Spain, ⁴Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ⁵Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁶Vall Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].